PE122699A1 - Antagonistas de receptores de vitronectina - Google Patents
Antagonistas de receptores de vitronectinaInfo
- Publication number
- PE122699A1 PE122699A1 PE1998000881A PE00088198A PE122699A1 PE 122699 A1 PE122699 A1 PE 122699A1 PE 1998000881 A PE1998000881 A PE 1998000881A PE 00088198 A PE00088198 A PE 00088198A PE 122699 A1 PE122699 A1 PE 122699A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- refers
- compound
- receptor antagonists
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5934297P | 1997-09-19 | 1997-09-19 | |
US6343897P | 1997-10-29 | 1997-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE122699A1 true PE122699A1 (es) | 2000-02-12 |
Family
ID=26738652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998000881A PE122699A1 (es) | 1997-09-19 | 1998-09-16 | Antagonistas de receptores de vitronectina |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1025090A4 (fr) |
JP (1) | JP2001517658A (fr) |
KR (1) | KR20010024141A (fr) |
CN (1) | CN1278250A (fr) |
AP (1) | AP2000001766A0 (fr) |
AR (1) | AR015446A1 (fr) |
AU (1) | AU738433B2 (fr) |
BG (1) | BG104314A (fr) |
BR (1) | BR9812340A (fr) |
CA (1) | CA2303487A1 (fr) |
CO (1) | CO5011087A1 (fr) |
DZ (1) | DZ2609A1 (fr) |
EA (1) | EA200000336A1 (fr) |
HU (1) | HUP0003641A3 (fr) |
ID (1) | ID24162A (fr) |
IL (1) | IL135028A0 (fr) |
MA (1) | MA26547A1 (fr) |
NO (1) | NO20001407D0 (fr) |
NZ (1) | NZ503389A (fr) |
OA (1) | OA11341A (fr) |
PE (1) | PE122699A1 (fr) |
PL (1) | PL339381A1 (fr) |
SK (1) | SK4082000A3 (fr) |
TR (1) | TR200000721T2 (fr) |
TW (1) | TW513303B (fr) |
WO (1) | WO1999015508A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
EP1150965A4 (fr) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine |
DE19936780A1 (de) * | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2004503540A (ja) * | 2000-06-15 | 2004-02-05 | ファルマシア・コーポレーション | インテグリンアンタゴニストとして有用なジヒドロスチルベンアルカン酸誘導体 |
JP2004513953A (ja) * | 2000-10-24 | 2004-05-13 | メルク エンド カムパニー インコーポレーテッド | ジベンズオキサゼピンαVインテグリン受容体アンタゴニスト |
RU2316337C2 (ru) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
CA2637387A1 (fr) | 2006-01-18 | 2007-07-26 | Simon Goodman | Traitement specifique utilisant des ligands de l'integrine destine a traiter un cancer |
EA017864B1 (ru) | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
CN102448497A (zh) | 2009-05-25 | 2012-05-09 | 默克专利有限公司 | 在癌症治疗中的西仑吉肽的持续给药 |
AU2015265571A1 (en) | 2014-05-30 | 2016-11-17 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH443281A (de) * | 1964-02-18 | 1967-09-15 | Hoffmann La Roche | Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen |
US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
DK0910563T3 (da) * | 1995-06-29 | 2003-09-01 | Smithkline Beecham Corp | Integrinreceptorantagonister |
US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
EP0946180A4 (fr) * | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | Procede de stimulation de la formation osseuse |
CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
-
1998
- 1998-09-16 AR ARP980104604A patent/AR015446A1/es not_active Application Discontinuation
- 1998-09-16 PE PE1998000881A patent/PE122699A1/es not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/fr active
- 1998-09-18 EP EP98947116A patent/EP1025090A4/fr not_active Withdrawn
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/fr not_active Application Discontinuation
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/pt not_active Application Discontinuation
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/ko not_active Application Discontinuation
- 1998-09-18 CA CA002303487A patent/CA2303487A1/fr not_active Abandoned
- 1998-09-18 PL PL98339381A patent/PL339381A1/xx unknown
- 1998-09-18 CN CN98810811A patent/CN1278250A/zh active Pending
- 1998-09-18 CO CO98053986A patent/CO5011087A1/es unknown
- 1998-09-18 MA MA25266A patent/MA26547A1/fr unknown
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/hu unknown
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/sk unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/ja not_active Withdrawn
- 1998-09-18 EA EA200000336A patent/EA200000336A1/ru unknown
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/xx unknown
- 1998-09-18 ID IDW20000468A patent/ID24162A/id unknown
- 1998-09-18 IL IL13502898A patent/IL135028A0/xx unknown
- 1998-09-23 TW TW087115535A patent/TW513303B/zh not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/no not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MA26547A1 (fr) | 2004-12-20 |
AP2000001766A0 (en) | 1998-09-18 |
CA2303487A1 (fr) | 1999-04-01 |
CO5011087A1 (es) | 2001-02-28 |
NZ503389A (en) | 2002-03-28 |
JP2001517658A (ja) | 2001-10-09 |
CN1278250A (zh) | 2000-12-27 |
WO1999015508A1 (fr) | 1999-04-01 |
HUP0003641A2 (en) | 2001-03-28 |
HUP0003641A3 (en) | 2002-10-28 |
ID24162A (id) | 2000-07-13 |
IL135028A0 (en) | 2001-05-20 |
EP1025090A1 (fr) | 2000-08-09 |
AU9397298A (en) | 1999-04-12 |
EA200000336A1 (ru) | 2000-10-30 |
KR20010024141A (ko) | 2001-03-26 |
DZ2609A1 (fr) | 2003-03-01 |
EP1025090A4 (fr) | 2000-11-08 |
BR9812340A (pt) | 2001-12-18 |
BG104314A (en) | 2001-01-31 |
PL339381A1 (en) | 2000-12-18 |
SK4082000A3 (en) | 2000-09-12 |
TR200000721T2 (tr) | 2000-11-21 |
TW513303B (en) | 2002-12-11 |
AR015446A1 (es) | 2001-05-02 |
NO20001407L (no) | 2000-03-17 |
OA11341A (en) | 2003-12-10 |
NO20001407D0 (no) | 2000-03-17 |
AU738433B2 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE122699A1 (es) | Antagonistas de receptores de vitronectina | |
UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
NZ336560A (en) | 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists | |
EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
TNSN90003A1 (fr) | Derives de 2-aminopyrimidinones utiles notamment comme antagonistes des neurotransmetteurs et procede pour leur preparation | |
BRPI0116237B8 (pt) | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". | |
BR9916790A (pt) | Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente | |
ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
HK1048469A1 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | |
ES2194223T3 (es) | Antagonistas de la integrina. | |
PT894084E (pt) | Derivados de acido cinamico e sua utilizacao como antagonistas de integrina | |
BR9810729B1 (pt) | composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. | |
IL168836A (en) | Pyrimidine-sulfamides and their use as endothelin receptor antagonist | |
BR9408325A (pt) | Composto composição farmacêutica e processo para a manufatura de um composto | |
DE60211935D1 (de) | Alkandiol derivate zur behandlung von knochenkrankheiten | |
PE20001563A1 (es) | Antagonistas del receptor de vitronectina | |
NO973652L (no) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist | |
WO2002022616A3 (fr) | Antagonistes du recepteur des integrines alpha v | |
AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
MXPA04001252A (es) | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. | |
AR026839A1 (es) | Compuestos quimicos | |
AR024411A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas. | |
FR2804958B1 (fr) | Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant | |
PE20000646A1 (es) | Terapia de combinacion para la fragilidad musculoesqueletica | |
ATE383341T1 (de) | Substituierte caprolactam carbonate und ether sowie deren verwendung als anti-tumor wirkstoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |